Management of cardiovascular disease risk in chronic inflammatory disorders

Nature Reviews Rheumatology

Volumn 5, Issue 4, 2009, Pages 208-217

  Kaplan, Mariana J ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATHEROSCLEROSIS; DISEASE MANAGEMENT; DISEASE PREDISPOSITION; HUMAN; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SYSTEMIC LUPUS ERYTHEMATOSUS;

ARTHRITIS, RHEUMATOID; ATHEROSCLEROSIS; DISEASE MANAGEMENT; DISEASE SUSCEPTIBILITY; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; RISK ASSESSMENT;

EID: 67650504852     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2009.29     Document Type: Article

References (146)

1. Fishbein, M. C. The vulnerable and unstable atherosclerotic plaque. Cardiovasc. Pathol. [doi:10.1016/j.carpath.2008.08.004] (2008).
2. Schillinger, M. et al. Inflammation and carotid artery—risk for atherosclerosis study (ICARAS). Circulation 111, 2203-2209 (2005).
3. Ridker, P M. et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N. Engl. J. Med. 336, 973-979 (1997).
4. Ridker, P M. et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N. Engl. J. Med. 342, 836-843 (2000).
5. Ross, R. Atherosclerosis is an inflammatory disease. Am. Heart J. 138, S419-S420 (1999).
6. Libby, P. Inflammation in atherosclerosis. Nature 420, 868-874 (2002).
7. Manzi, S. et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am. J. Epidemiol. 145, 408-415 (1997).
8. Maradit-Kremers, H. et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum. 52, 402-411 (2005).
9. Solomon, D. H. et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 107, 1303-1307 (2003).
10. Avina-Zubieta, J. A. et al. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum. 59, 1690-1697 (2008).
11. Solomon, D. H. et al. Cardiovascular risk factors in women with and without rheumatoid arthritis. Arthritis Rheum. 50, 3444-3449 (2004).
12. Sodergren, A. et al. Increased incidence of and impaired prognosis after acute myocardial infarction among patients with seropositive rheumatoid arthritis. Ann. Rheum. Dis. 66, 263-266 (2007).
13. Goodson, N. J. et al. Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients. Arthritis Rheum. 46, 2010-2019 (2002).
14. Bergholm, R. et al. Impaired responsiveness to NO in newly diagnosed patients with rheumatoid arthritis. Arterioscler. Thromb. Vasc. Biol. 22, 1637-1641 (2002).
15. Wallberg-Jonsson, S. et al. Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden. J. Rheumatol. 24, 445-451 (1997).
16. Davis, J. M. et al. The presentation and outcome of heart failure in patients with rheumatoid arthritis differs from that in the general population. Arthritis Rheum. 58, 2603-2611 (2008).
17. Bhatia, G. S. & Davis, R. C. Rheumatoid arthritis and heart failure. Am. J. Med. 117, 709 (2004).
18. Rudominer, R. L. et al. Independent association of rheumatoid arthritis with increased left ventricular mass but not with reduced ejection fraction. Arthritis Rheum. 60, 22-29 (2009).
19. Goodson, N. et al. Cardiovascular admissions and mortality in an inception cohort of patients with rheumatoid arthritis with an onset in the 1980s and 1990s. Ann. Rheum. Dis. 64, 1595-1601 (2005).
20. Park, Y. B. et al. Atherosclerosis in rheumatoid arthritis: morphologic evidence obtained by carotid ultrasound. Arthritis Rheum. 46, 1714-1719 (2002).
21. Kumeda, Y et al. Increased thickness of the arterial intima-media detected by ultrasonography in patients with rheumatoid arthritis. Arthritis Rheum. 46, 1489-1497 (2002).
22. Warrington, K. J. et al. Rheumatoid arthritis is an independent risk factor for multi-vessel coronary artery disease: a case control study. Arthritis Res. Ther. 7, R984-R991 (2005).
23. Wallberg-Jonsson, S. et al. Which factors are related to the presence of atherosclerosis in rheumatoid arthritis? Scand. J. Rheumatol. 33, 373-379 (2004).
24. Herrmann, M. et al. Etiopathogenesis of systemic lupus erythematosus. Immunol. Today 21, 424-426 (2000).
25. Kao, A. H. et al. Update on vascular disease in systemic lupus erythematosus. Curr. Opin. Rheumatol. 15, 519-527 (2003).
26. Ward, M. M. Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum. 42, 338-346 (1999).
27. Esdaile, J. M. et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 44, 2331-2337 (2001).
28. Rahman, P et al. Contribution of traditional risk factors to coronary artery disease in patients with systemic lupus erythematosus. J. Rheumatol. 26, 2363-2368 (1999).
29. Rajagopalan, S. et al. Endothelial cell apoptosis in systemic lupus erythematosus: a common pathway for abnormal vascular function and thrombosis propensity. Blood 103, 3677-3683 (2004).
30. Lima, D. S. et al. Brachial endothelial function is impaired in patients with systemic lupus erythematosus. J. Rheumatol. 29, 292-297 (2002).
31. Pieretti, J. et al. Systemic lupus erythematosus predicts increased left ventricular mass. Circulation 116, 419-426 (2007).
32. Bruce, I. N. et al. Single photon emission computed tomography dual isotope myocardial perfusion imaging in women with systemic lupus erythematosus. I. Prevalence and distribution of abnormalities. J. Rheumatol. 27, 2372-2377 (2000).
33. Roman, M. J. et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N. Engl. J. Med. 349, 2399-2406 (2003).
34. Asanuma, Y et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N. Engl. J. Med. 349, 2407-2415 (2003).
35. Sherer, Y et al. Thickened carotid artery intima- media in rheumatoid arthritis is associated with elevated anticardiolipin antibodies. Lupus 16, 259-264 (2007).
36. Roman, M. J. et al. Rate and determinants of progression of atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 56, 3412-3419 (2007).
37. Gresele, P. et al. Patients with primary antiphospholipid antibody syndrome and without associated vascular risk factors present a normal endothelial function. Thromb. Res. 123, 444-451 (2009).
38. Bilora, F. & Sartori, M. Flow-mediated arterial dilation in primary antiphospholipid syndrome. Angiology [doi:10.1177/0003319708315304] (2008).
39. Belizna, C. et al. Antiphospholipid antibodies induce vascular functional changes in mice: a mechanism of vascular lesions in antiphospholipid syndrome? Lupus 17, 185-194 (2008).
40. Der, H. et al. Impaired endothelial function and increased carotid intima-media thickness in association with elevated von Willebrand antigen level in primary antiphospholipid syndrome. Lupus 16, 497-503 (2007).
41. No authors listed. Subclinical and clinical manifestations of atherosclerosis in antiphospholipid syndrome [Russian]. Ter. Arkh. 80, 60-67 (2008).
42. Farzaneh-Far, A. et al. Relationship of antiphospholipid antibodies to cardiovascular manifestations of systemic lupus erythematosus. Arthritis Rheum. 54, 3918-3925 (2006).
43. Meroni, P. L. et al. Anti-beta 2 glycoprotein I antibodies and the risk of myocardial infarction in young premenopausal women. J. Thromb. Haemost. 5, 2421-2428 (2007).
44. Gelfand, J. M. et al. Prevalence and treatment of psoriasis in the United Kingdom: a population- based study. Arch. Dermatol. 141, 1537-1541 (2005).
45. Ludwig, R. J. et al. Psoriasis: a possible risk factor for development of coronary artery calcification. Br. J. Dermatol. 156, 271-276 (2007).
46. Shapiro, J. et al. The association between psoriasis, diabetes mellitus, and atherosclerosis in Israel: a case-control study. J. Am. Acad. Dermatol. 56, 629-634 (2007).
47. Gelfand, J. M. et al. Risk of myocardial infarction in patients with psoriasis. JAMA 296, 1735-1741 (2006).
48. Poikolainen, K. et al. Excess mortality related to alcohol and smoking among hospital-treated patients with psoriasis. Arch. Dermatol. 135, 1490-1493 (1999).
49. Timar, O. et al. Increased arterial stiffness as the marker of vascular involvement in systemic sclerosis. J. Rheumatol. 35, 1329-1333 (2008).
50. Hettema, M. E. et al. Early atherosclerosis in systemic sclerosis and its relation to disease or traditional risk factors. Arthritis Res. Ther. 10, R49 (2008).
51. Khurma, V. et al. A pilot study of subclinical coronary atherosclerosis in systemic sclerosis: coronary artery calcification in cases and controls. Arthritis Rheum. 59, 591-597 (2008).
52. Follansbee, W. P et al. Physiologic abnormalities of cardiac function in progressive systemic sclerosis with diffuse scleroderma. N. Engl. J. Med. 310, 142-148 (1984).
53. Vignaux, O. et al. Evaluation of the effect of nifedipine upon myocardial perfusion and contractility using cardiac magnetic resonance imaging and tissue Doppler echocardiography in systemic sclerosis. Ann. Rheum. Dis. 64, 1268-1273 (2005).
54. Lehtinen, K. Mortality and causes of death in 398 patients admitted to hospital with antylosing spondylitis. Ann. Rheum. Dis. 52, 174-176 (1993).
55. Mathieu, S. et al. Trend towards increased arterial stiffness or intima-media thickness in antylosing spondylitis patients without clinically evident cardiovascular disease. Rheumatology (Oxford) 47, 1203-1207 (2008).
56. Choe, J. Y. et al. No differences of carotid intima-media thickness between young patients with ankylosing spondylitis and healthy controls. Joint Bone Spine 75, 548-553 (2008).
57. Han, C. et al. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J. Rheumatol. 33, 2167-2172 (2006).
58. Sari, I. et al. Impaired endothelial function in patients with ankylosing spondylitis. Rheumatology (Oxford) 45, 283-286 (2006).
59. Caliskan, M. et al. Impaired coronary microvascular and left ventricular diastolic functions in patients with ankylosing spondylitis. Atherosclerosis 196, 306-312 (2008).
60. Pirildar, T. et al. Endothelial dysfunction in patients with primary Sjogren's syndrome. Rheumatol. Int. 25, 536-539 (2005).
61. Vaudo, G. et al. Precocious intima-media thickening in patients with primary Sjogren's syndrome. Arthritis Rheum. 52, 3890-3897 (2005).
62. Pasceri, V. & Yeh, E. T. A tale of two diseases: atherosclerosis and rheumatoid arthritis. Circulation 100, 2124-2126 (1999).
63. Hurlimann, D. et al. Anti-tumor necrosis factor- alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 106, 2184-2187 (2002).
64. Svenson, K. L. et al. Impaired glucose handling in active rheumatoid arthritis: relationship to peripheral insulin resistance. Metabolism 37, 125-130 (1988).
65. Sattar, N. et al. Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 108, 2957-2963 (2003).
66. Werner, N. et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N. Engl. J. Med. 353, 999-1007 (2005).
67. Grisar, J. et al. Depletion of endothelial progenitor cells in the peripheral blood of patients with rheumatoid arthritis. Circulation 111, 204-211 (2005).
68. Denny, M. F. et al. Interferon-alpha promotes abnormal vasculogenesis in lupus: a potential pathway for premature atherosclerosis. Blood 110, 2907-2915 (2007).
69. Kuwana, M. et al. Defective vasculogenesis in systemic sclerosis. Lancet 364, 603-610 (2004).
70. Grisar, J. et al. Systemic lupus erythematosus patients exhibit functional deficiencies of endothelial progenitor cells. Rheumatology (Oxford) 47, 1476-1483 (2008).
71. Egan, C. G. et al. Endothelial progenitor cells and colony-forming units in rheumatoid arthritis: association with clinical characteristics. Rheumatology (Oxford) 47, 1484-1488 (2008).
72. Verma, S. et al. C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: further evidence of a mechanistic link between C-reactive protein and cardiovascular disease. Circulation 109, 2058-2067 (2004).
73. Ablin, J. N. et al. Effect of anti-TNFalpha treatment on circulating endothelial progenitor cells (EPCs) in rheumatoid arthritis. Life Sci. 79, 2364-2369 (2006).
74. Lee, P Y. et al. Type I interferon as a novel risk factor for endothelial progenitor cell depletion and endothelial dysfunction in systemic lupus erythematosus. Arthritis Rheum. 56, 3759-3769 (2007).
75. Ezekowitz, R. A. et al. Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N. Engl. J. Med. 326, 1456-1463 (1992).
76. Arlestig, L. et al. Polymorphism of genes related to cardiovascular disease in patients with rheumatoid arthritis. Clin. Exp. Rheumatol. 25, 866-871 (2007).
77. Liuzzo, G. et al. Monoclonal T-cell proliferation and plaque instability in acute coronary syndromes. Circulation 101, 2883-2888 (2000).
78. Nakajima, T. et al. De novo expression of killer immunoglobulin-like receptors and signaling proteins regulates the cytotoxic function of CD4 T cells in acute coronary syndromes. Circ. Res. 93, 106-113 (2003).
79. − T cells in RA patients and correlation with atherosclerotic damage. Ann. NY Acad. Sci. 1107, 32-41 (2007).
80. Bryl, E. et al. Modulation of CD28 expression with anti-tumor necrosis factor alpha therapy in rheumatoid arthritis. Arthritis Rheum. 52, 2996-3003 (2005).
81. Sitia, S. et al. Cardiovascular involvement in systemic autoimmune diseases. Autoimmun. Rev. [doi:10.1016/j.autrev.2008.08.004] (2008).
82. Margutti, P et al. Autoantibodies to the C-terminal subunit of RLIP76 induce oxidative stress and endothelial cell apoptosis in immune-mediated vascular diseases and atherosclerosis. Blood 111, 4559-4570 (2008).
83. Bruce, I. N. 'Not only.but also': factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus. Rheumatology (Oxford) 44, 1492-1502 (2005).
84. Kobayashi, K. et al. Distinguished effects of antiphospholipid antibodies and anti-oxidized LDL antibodies on oxidized LDL uptake by macrophages. Lupus 16, 929-938 (2007).
85. Cederholm, A. & Frostegard, J. Annexin A5 as a novel player in prevention of atherothrombosis in SLE and in the general population. Ann. NY Acad. Sci. 1108, 96-103 (2007).
86. Hafstrom, I. et al. Effects of low-dose prednisolone on endothelial function, atherosclerosis, and traditional risk factors for atherosclerosis in patients with rheumatoid arthritis-- a randomized study. J. Rheumatol. 34, 1810-1816 (2007).
87. del Rincon, I. et al. Effect of glucocorticoids on the arteries in rheumatoid arthritis. Arthritis Rheum. 50, 3813-3822 (2004).
88. Manzi, S. et al. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum. 42, 51-60.
89. Nashel, D. J. Is atherosclerosis a complication of long-term corticosteroid treatment? Am. J. Med. 80, 925-929 (1986).
90. Wolfe, F. The effect of smoking on clinical, laboratory, and radiographic status in rheumatoid arthritis. J. Rheumatol. 27, 630-637.
91. Symmons, D. P. et al. Blood transfusion, smoking, and obesity as risk factors for the development of rheumatoid arthritis: results from a primary care-based incident case-control study in Norfolk, England. Arthritis Rheum. 40, 1955-1961 (1997).
92. Calvo-Alen, J. et al. Systemic lupus erythematosus in a multiethnic US cohort: XXXIV. Deficient mannose-binding lectin exon 1 polymorphisms are associated with cerebrovascular but not with other arterial thrombotic events. Arthritis Rheum. 54, 1940-1945 (2006).
93. Wolfe, F. & Michaud, K. The risk of myocardial infarction and pharmacologic and nonpharmacologic myocardial infarction predictors in rheumatoid arthritis: A cohort and nested case-control analysis. Arthritis Rheum. 58, 2612-2621 (2008).
94. Petri, M. et al. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am. J. Med. 93, 513-519 (1992).
95. Dessein, P. H. et al. Traditional and nontraditional cardiovascular risk factors are associated with atherosclerosis in rheumatoid arthritis. J. Rheumatol. 32, 435-442 (2005).
96. Dahlqvist, S. R. et al. Tumor necrosis factor receptor type II (exon 6) and interleukin-6 (-174) gene polymorphisms are not associated with family history but tumor necrosis factor receptor type II is associated with hypertension in patients with rheumatoid arthritis from northern Sweden. Arthritis Rheum. 46, 3096-3098 (2002).
97. Frostegard, J. Atherosclerosis in patients with autoimmune disorders. Arterioscler. Thromb. Vasc. Biol. 25, 1776-1785 (2005).
98. van Halm, V. P et al. Lipids and inflammation: serial measurements of the lipid profile of blood donors who later developed rheumatoid arthritis. Ann. Rheum. Dis. 66, 184-188 (2007).
99. de Carvalho, J. F. et al. Systemic lupus erythematosus and "lupus dyslipoproteinemia". Autoimmun. Rev. 7, 246-250 (2008).
100. Svenungsson, E. et al. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 104, 1887-1893 (2001).
101. Sari, R. A. et al. Serum lipoprotein(a) level and its clinical significance in patients with systemic lupus erythematosus. Clin. Rheumatol. 21, 520-524 (2002).
102. McMahon, M. et al. Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum. 54, 2541-2549 (2006).
103. Pedersen, L. M. et al. Microalbuminuria in patients with rheumatoid arthritis. Ann. Rheum. Dis. 54, 189-192 (1995).
104. Shulman, G. I. Cellular mechanisms of insulin resistance. J. Clin. Invest. 106, 171-176 (2000).
105. Evans, J. L. et al. The molecular basis for oxidative stress-induced insulin resistances. Antioxid. Redox Signal. 7, 1040-1052 (2005).
106. Dessein, P. H. et al. Effects of disease modifying agents and dietary intervention on insulin resistance and dyslipidemia in inflammatory arthritis: a pilot study. Arthritis Res. 4, R12 (2002).
107. Hallgren, R. & Berne, C. Glucose intolerance in patients with chronic inflammatory diseases is normalized by glucocorticoids. Acta Med. Scand. 213, 351-355 (1983).
108. Dessein, P H. et al. Cardiovascular risk in rheumatoid arthritis versus osteoarthritis: acute phase response related decreased insulin sensitivity and high-density lipoprotein cholesterol as well as clustering of metabolic syndrome features in rheumatoid arthritis. Arthritis Res. 4, R5 (2002).
109. Dessein, P H. et al. Subclinical hypothyroidism is associated with insulin resistance in rheumatoid arthritis. Thyroid 14, 443-446 (2004).
110. Dessein, P. H. et al. The acute phase response does not fully predict the presence of insulin resistance and dyslipidemia in inflammatory arthritis. J. Rheumatol. 29, 462-466 (2002).
111. Kiortsis, D. N. et al. Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis. Ann. Rheum. Dis. 64, 765-766 (2005).
112. Rask-Madsen, C. et al. Tumor necrosis factor- alpha inhibits insulin's stimulating effect on glucose uptake and endothelium-dependent vasodilation in humans. Circulation 108, 1815-1821 (2003).
113. Chung, C. P et al. Inflammation-associated insulin resistance: differential effects in rheumatoid arthritis and systemic lupus erythematosus define potential mechanisms. Arthritis Rheum. 58, 2105-2112 (2008).
114. Malesci, D. et al. High prevalence of metabolic syndrome in patients with ankylosing spondylitis. Clin. Rheumatol. 26, 710-714 (2007).
115. Von Feldt, J. M. et al. Homocysteine levels and disease duration independently correlate with coronary artery calcification in patients with systemic lupus erythematosus. Arthritis Rheum. 54, 2220-2227 (2006).
116. Kremers, H. M. et al. High ten-year risk of cardiovascular disease in newly diagnosed rheumatoid arthritis patients: a population- based cohort study. Arthritis Rheum. 58, 2268-2274 (2008).
117. National Heart Lung and Blood Institute. Cholesterol Guidelines (2001) [www.nhlbi.nih. gov/guidelines/cholesterol/atglance.pdf].
118. National Heart Lung and Blood Institute. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (2004) [www.nhlbi.nih.gov/guidelines/hypertension].
119. Kallberg, H. et al. Gene-gene and gene- environment interactions involving HLA-DRB1, PTPN22, and smoking in two subsets of rheumatoid arthritis. Am. J. Hum. Genet. 80, 867-875 (2007).
120. McCarey, D. W. et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 363, 2015-2021 (2004).
121. Van Doornum, S. et al. Atorvastatin reduces arterial stiffness in patients with rheumatoid arthritis. Ann. Rheum. Dis. 63, 1571-1575 (2004).
122. Ferreira, G. A. et al. Atorvastatin therapy improves endothelial-dependent vasodilation in patients with systemic lupus erythematosus: an 8 weeks controlled trial. Rheumatology (Oxford) 46, 1560-1565 (2007).
123. Bishop-Bailey, D. Peroxisome proliferator- activated receptors in the cardiovascular system. Br. J. Pharmacol. 129, 823-834 (2000).
124. Chan, A. T. et al. Nonsteroidal anti-inflammatory drugs, acetaminophen, and the risk of cardiovascular events. Circulation 113, 1578-1587 (2006).
125. Bresalier, R. S. et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N. Engl. J. Med. 352, 1092-1102 (2005).
126. Cannon, C. P. et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 368, 1771-1781 (2006).
127. Alarcon, G. S. et al. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Ann. Rheum. Dis. 66, 1168-1172 (2007).
128. Sachet, J. C. et al. Chloroquine increases low-density lipoprotein removal from plasma in systemic lupus patients. Lupus 16, 273-278 (2007).
129. Wasko, M. C. et al. Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis. JAMA 298, 187-193 (2007).
130. Doria, A. et al. Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Ann. Rheum. Dis. 62, 1071-1077 (2003).
131. Toms, T. E. et al. Lack of association between glucocorticoid use and presence of the metabolic syndrome in patients with rheumatoid arthritis: a cross sectional study. Arthritis Res. Ther. 10, R145 (2008).
132. Panoulas, V. F. et al. Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis. Rheumatology (Oxford) 47, 72-75 (2008).
133. Boers, M. et al. Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. Ann. Rheum. Dis. 62, 842-845 (2003).
134. Choi, H. K. et al. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 359, 1173-1177 (2002).
135. Krause, D. et al. Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis. Arthritis Rheum. 43, 14-21 (2000).
136. van Halm, V. P et al. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study. Arthritis Res. Ther. 8, R151 (2006).
137. Bernatsty, S. et al. Anti-rheumatic drug use and risk of hospitalization for congestive heart failure in rheumatoid arthritis. Rheumatology (Oxford) 44, 677-680 (2005).
138. Gibson, W. T. & Hayden, M. R. Mycophenolate mofetil and atherosclerosis: results of animal and human studies. Ann. NY Acad. Sci. 1110, 209-221 (2007).
139. Jacobsson, L. T. et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J. Rheumatol. 32, 1213-1218 (2005).
140. Popa, C. et al. Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis. Ann. Rheum. Dis. 64, 303-305 (2005).
141. Gonzalez-Juanatey, C. et al. Short-term improvement of endothelial function in rituximab-treated rheumatoid arthritis patients refractory to tumor necrosis factor alpha blocker therapy. Arthritis Rheum. 59, 1821-1824 (2008).
142. Alpaslan, M. et al. Doppler echocardiographic evaluation of ventricular function in patients with rheumatoid arthritis. Clin. Rheumatol. 22, 84-88 (2003).
143. Del Rincon, I. et al. Association between carotid atherosclerosis and markers of inflammation in rheumatoid arthritis patients and healthy subjects. Arthritis Rheum. 48, 1833-1840 (2003).
144. del Rincon, I. D. et al. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum. 44, 2737-2745 (2001).
145. Biyik, I. et al. Echocardiographic and clinical abnormalities in patients with psoriasis. J. Int. Med. Res. 34, 632-639 (2006).
146. Kimball, A. B. et al. Cardiovascular disease and risk factors among psoriasis patients in two US healthcare databases, 2001-2002. Dermatology 217, 27-37 (2008).